Sunesis
Showing 1 - 17 of 17
MDS Trial in Saint Louis (vosaroxin, Azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes
-
Saint Louis, MissouriWashington University School of Medicine
Mar 23, 2022
Leukemia Trial in Houston (Vosaroxin, Decitabine)
Completed
- Leukemia
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 13, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Trial in Essen, Oldenburg, Ulm (Vosaroxin,
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
-
Essen, Germany
- +2 more
Oct 27, 2020
Myelodysplastic Syndrome Trial in New York (Vosaroxin)
Completed
- Myelodysplastic Syndrome
-
New York, New YorkWeill Cornell Medical College
Jan 24, 2019
NSCLC Trial in United States (SNS-595 Injection)
Completed
- Carcinoma, Non-Small-Cell Lung
- SNS-595 Injection
-
Scottsdale, Arizona
- +3 more
Dec 8, 2017
Carcinoma, Small Cell, Small Cell Lung Cancer Trial in Canada, United States (SNS-595)
Completed
- Carcinoma, Small Cell
- Small Cell Lung Cancer
-
Sacramento, California
- +16 more
Oct 19, 2017
Acute Myeloid Leukemia Trial in Worldwide (vosaroxin + cytarabine, + cytarabine)
Completed
- Acute Myeloid Leukemia
- vosaroxin + cytarabine
- placebo + cytarabine
-
La Jolla, California
- +123 more
Jul 25, 2018
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (SNS-032 Injection)
Completed
- B-lymphoid Malignancies
- +3 more
- SNS-032 Injection
-
Duarte, California
- +5 more
Apr 7, 2017
Acute Myeloid Leukemia Trial in United States (Voreloxin injection and cytarabine)
Completed
- Acute Myeloid Leukemia
- Voreloxin injection and cytarabine
-
Denver, Colorado
- +8 more
Dec 11, 2017
Epithelial Ovarian Cancer Trial in Canada, United States (Voreloxin Injection)
Completed
- Epithelial Ovarian Cancer
- Voreloxin Injection
-
Scottsdale, Arizona
- +19 more
Jun 28, 2017
Tumors Trial in United States (SNS-032 Injection)
Completed
- Tumors
- SNS-032 Injection
-
Scottsdale, Arizona
- +5 more
Jun 5, 2012